What is Collegium Pharmaceutical, Inc.'s belbuca — 2029?

Collegium Pharmaceutical, Inc. (COLL) reported belbuca — 2029 of $0 in Q1 2026.

What does belbuca — 2029 mean?

The projected amortization expense specifically allocated to Belbuca-related intangible assets for the fiscal year 2029. This metric is used to estimate the long-term non-cash impact on profitability as the asset approaches the end of its amortizable life.

Collegium Pharmaceutical, Inc. COLL Belbuca — 2029

Similar metrics at other companies

BKSY2029

$0-100%

BKSY2027

$0-100%

GD2029

$147M-12.0%

LHX2029

$403M—

BX2029

$17M+95,406%

STT2029

$132M-21.4%

Other financials

Income statement

See full

Revenue$193.5M+8.9%

Gross profit$117.2M+20.5%

Operating income$30.9M+42.5%

Net income$14.5M+500%

EPS (diluted)$0.40+471%

Balance sheet

See full

Cash & equivalents$289.6M+147%

Total debt$5.2M-19.5%

Total equity$312.4M+33.3%

Total assets$1.7B+1.3%

Cash flow

See full

Operating cash flow$57.1M+3.1%

CapEx$270.0K-66.2%

Free cash flow$56.8M+4.1%

Valuation

See full

Market cap$1.15B+20.4%

Enterprise value$869.67M+2.5%

P/E15.4×-6.4×

P/S1.5×0.0×

Profitability

See full

Gross margin60.7%+3.0pp

Operating margin23.7%+2.3pp

Net margin9.4%+2.8pp

FCF margin41.4%+10.4pp

Returns & leverage

See full

Return on equity27.4%+8.2pp

Debt / equity0×0.0×

Current ratio1.7×+0.6×

Where this comes from

Reported directly by Collegium Pharmaceutical, Inc. in its filing.

Tagged under the XBRL concept us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearThree.

The official record: Collegium Pharmaceutical, Inc.’s 10-Q, filed May 7, 2026, on SEC EDGAR. View the filing →

Ask your AI about Collegium Pharmaceutical, Inc.'s belbuca — 2029.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI

Claude

Questions, answered.

What is Collegium Pharmaceutical, Inc.'s belbuca — 2029?: Collegium Pharmaceutical, Inc. (COLL) reported belbuca — 2029 of $0 in Q1 2026.
What does belbuca — 2029 mean?: The projected amortization expense specifically allocated to Belbuca-related intangible assets for the fiscal year 2029. This metric is used to estimate the long-term non-cash impact on profitability as the asset approaches the end of its amortizable life.